Iqvia Holdings Inc (IQV) Stock Price, Quote & News

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 919 998 2000

Website: www.iqvia.com

Address:

2400 Ellis Road, Durham, United States

BillionerOfKing May. 8 at 5:17 AM

$IQV Current Stock Price: $178.69 Contracts to trade: $180.0 IQV May 15 2026 Call Entry: $3.60 Exit: $6.72 ROI: 87% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AXLFI_HQ May. 6 at 11:38 PM

$IQV Q1 2026 earnings reveal broad-based strength across technology, financial services, industrials, healthcare, and energy sectors with companies consistently beating expectations and raising guidance, signaling management confidence in earnings durability and accelerated capital returns. Learn more: https://axlfi.com/themes/228

0 · Reply

BillionerOfKing May. 6 at 10:55 PM

$IQV Current Stock Price: $176.39 Contracts to trade: $175.0 IQV May 15 2026 Call Entry: $4.40 Exit: $6.95 ROI: 58% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CapitalMonk May. 6 at 11:10 AM

$IQV Price: $176.42 (+9.62%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.70% RSI: 48.6 | Momentum: Moderate Volume: +138.6% vs avg Volatility: 3.39% Support: $154.50 | Resistance: $180.98 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

1986iamwallstreet May. 5 at 11:29 AM

$IQV 🩸🩸🩸🩸🩸

0 · Reply

StocktwitsEarnings May. 5 at 11:08 AM

$IQV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.63 up 14.79% YoY • Reported revenue of $4.15B up 8.41% YoY • IQVIA is reaffirming full-year 2026 revenue guidance between $17.15B and $17.35B and Adjusted EBITDA between $3.98B and $4.03B, while raising Adjusted Diluted EPS guidance to $12.65-$12.95.

0 · Reply

KayJ_ May. 4 at 9:58 PM

$NTRA $LOGI $IQV $CASY show me

0 · Reply

NasdaqPulse Apr. 24 at 1:39 PM

$NVO catching a bid in the PM (+3.5%) while $LLY slips — and the reason matters. 👉Click to view @NasdaqPulse for timely updates amid the volatility. Fresh data (via IQVIA / $IQV) shows weekly scripts for Novo’s Wegovy outpacing Lilly’s Zepbound + Foundayo. That’s a real-time demand signal, not just hype. Market reaction is clear: ➡️ $NVO strength on share gains ➡️ $LLY under pressure on relative slowdown This isn’t just a one-day move — it’s positioning around who’s actually winning the GLP-1 race right now. If script momentum holds, expect sentiment + flows to keep rotating. Obesity drug war = follow the prescriptions, not the headlines.

0 · Reply

AcceleratorModel Apr. 2 at 6:11 AM

$IQV important level here— see it if holds before earnings

0 · Reply

RunnerSignals Mar. 24 at 8:38 PM

$FIG $IQV $JEF $CHWY $AG Top stock upgrades today in the BUZZ https://stocksrunner.com/news/2026-03-24-top-stock-upgrades-today-in-the-buzz

0 · Reply

Iqvia approves $2B increase to share repurchase authorization

May 7, 2026, 5:15 PM EDT - 1 day ago

IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization

2026-05-07T19:12:44.000Z - 1 day ago

Iqvia price target lowered to $225 from $240 at Morgan Stanley

May 6, 2026, 4:15 PM EDT - 2 days ago

IQVIA CFO to Speak at Bank of America Health Care Conference 2026

May 5, 2026, 9:00 AM EDT - 3 days ago

IQVIA Holdings Earnings Call Transcript: Q1 2026

May 5, 2026, 7:00 AM EDT - 3 days ago

IQVIA Reports First-Quarter 2026 Results

Apr 15, 2026, 4:15 PM EDT - 23 days ago

IQVIA to Announce First-Quarter 2026 Results on May 5, 2026

2026-04-08T13:17:34.000Z - 4 weeks ago

Iqvia price target lowered to $185 from $225 at Evercore ISI

Mar 16, 2026, 4:30 PM EDT - 7 weeks ago

IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences

Mar 12, 2026, 9:30 AM EDT - 2 months ago

IQVIA Holdings Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 9:20 AM EDT - 2 months ago

IQVIA Holdings Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T09:50:09.000Z - 2 months ago

Iqvia upgraded to Buy from Hold at TD Cowen

2026-03-09T09:40:46.000Z - 2 months ago

Iqvia price target raised to $213 from $174 at TD Cowen

2026-03-06T11:25:41.000Z - 2 months ago

Iqvia upgraded to Overweight from Equal Weight at Barclays

2026-03-06T11:11:16.000Z - 2 months ago

Iqvia upgraded to Overweight from Equal Weight at Barclays

2026-03-03T10:25:11.000Z - 2 months ago

Iqvia initiated with an Outperform at RBC Capital

Mar 2, 2026, 4:30 PM EST - 2 months ago

IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 4:15 PM EST - 2 months ago

IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference

Feb 27, 2026, 4:47 PM EST - 2 months ago

IQVIA Releases its 2025 Sustainability Report

Feb 26, 2026, 11:00 AM EST - 2 months ago

IQVIA Holdings Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day

2026-02-25T12:36:22.000Z - 2 months ago

Iqvia to acquire certain discovery services assets from Charles River

CRL

Feb 25, 2026, 7:00 AM EST - 2 months ago

IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities

Feb 24, 2026, 9:01 AM EST - 2 months ago

10 stocks Wall Street expects to roar back after dropping at least 20% in 2026

APP BKNG COF CSGP KKR NOW ORCL

2026-02-23T12:43:53.000Z - 2 months ago

Iqvia price target lowered to $215 from $266 at Mizuho

2026-02-19T13:35:17.000Z - 2 months ago

Iqvia price target lowered to $245 from $290 at Truist

Feb 18, 2026, 4:15 PM EST - 2 months ago

IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day

2026-02-17T14:11:16.000Z - 2 months ago

Iqvia price target lowered to $174 from $245 at TD Cowen

2026-02-11T14:10:21.000Z - 3 months ago

Iqvia price target lowered to $240 from $265 at Morgan Stanley

2026-02-10T13:26:01.000Z - 3 months ago

Iqvia announces collaboration with Duke Clinical Research Institute

Feb 10, 2026, 8:00 AM EST - 3 months ago

IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions

2026-02-06T13:37:45.000Z - 3 months ago

Iqvia price target lowered to $240 from $280 at UBS

Feb 5, 2026, 9:07 AM EST - 3 months ago

IQVIA forecasts weak annual profit on higher interest expenses

Feb 5, 2026, 9:00 AM EST - 3 months ago

IQVIA Holdings Earnings Call Transcript: Q4 2025

Feb 5, 2026, 7:00 AM EST - 3 months ago

IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Jan 29, 2026, 8:00 AM EST - 3 months ago

IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration

Jan 22, 2026, 4:05 PM EST - 3 months ago

IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

Jan 20, 2026, 4:45 PM EST - 3 months ago

IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

Dec 2, 2025, 8:00 AM EST - 5 months ago

IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

Nov 11, 2025, 12:30 PM EST - 6 months ago

IQVIA Holdings Transcript: UBS Global Healthcare Conference 2025

Nov 5, 2025, 4:15 PM EST - 6 months ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Oct 28, 2025, 9:00 AM EDT - 6 months ago

IQVIA Holdings Earnings Call Transcript: Q3 2025

Oct 28, 2025, 7:53 AM EDT - 6 months ago

IQVIA narrows annual profit forecast amid continued research contract cancellations

Oct 28, 2025, 7:00 AM EDT - 6 months ago

IQVIA Reports Third-Quarter 2025 Results

Oct 21, 2025, 4:15 PM EDT - 7 months ago

IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

Sep 30, 2025, 4:15 PM EDT - 7 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 26, 2025, 9:40 AM EDT - 8 months ago

ILMN Stock vs. IQV Stock

ILMN

Sep 16, 2025, 8:00 AM EDT - 8 months ago

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

Sep 10, 2025, 8:00 AM EDT - 8 months ago

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

Sep 2, 2025, 9:41 AM EDT - 8 months ago

IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:00 AM EDT - 8 months ago

IQVIA Announces CFO Transition in Early 2026

Aug 28, 2025, 8:00 AM EDT - 9 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX MRNA SANA

Aug 19, 2025, 12:00 PM EDT - 9 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW

Aug 18, 2025, 9:00 AM EDT - 9 months ago

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

VEEV

Jul 22, 2025, 9:00 AM EDT - 10 months ago

IQVIA Holdings Earnings Call Transcript: Q2 2025

Jul 22, 2025, 8:42 AM EDT - 10 months ago

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

Jul 22, 2025, 7:00 AM EDT - 10 months ago

IQVIA Reports Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 11 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jun 16, 2025, 9:00 AM EDT - 11 months ago

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'

Jun 11, 2025, 7:00 AM EDT - 11 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 2, 2025, 4:37 PM EDT - 1 year ago

IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 1 year ago

IQVIA Announces Offering of Senior Notes

May 27, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

RNTX

May 16, 2025, 8:00 AM EDT - 1 year ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 13, 2025, 5:20 PM EDT - 1 year ago

IQVIA Holdings Transcript: BofA Securities 2025 Healthcare Conference

May 7, 2025, 4:15 PM EDT - 1 year ago

IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

May 6, 2025, 9:00 AM EDT - 1 year ago

IQVIA Holdings Earnings Call Transcript: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

IQVIA Reports First-Quarter 2025 Results

Apr 28, 2025, 9:00 AM EDT - 1 year ago

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

Apr 23, 2025, 9:00 AM EDT - 1 year ago

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

Apr 21, 2025, 4:15 PM EDT - 1 year ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

Mar 10, 2025, 9:00 AM EDT - 1 year ago

IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

Mar 4, 2025, 11:10 AM EST - 1 year ago

IQVIA Holdings Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:00 AM EST - 1 year ago

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

Feb 25, 2025, 3:00 PM EST - 1 year ago

Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation

Feb 24, 2025, 9:00 AM EST - 1 year ago

IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence

BillionerOfKing May. 8 at 5:17 AM

0 · Reply

AXLFI_HQ May. 6 at 11:38 PM

0 · Reply

BillionerOfKing May. 6 at 10:55 PM

0 · Reply

CapitalMonk May. 6 at 11:10 AM

0 · Reply

1986iamwallstreet May. 5 at 11:29 AM

$IQV 🩸🩸🩸🩸🩸

0 · Reply

StocktwitsEarnings May. 5 at 11:08 AM

0 · Reply

KayJ_ May. 4 at 9:58 PM

$NTRA $LOGI $IQV $CASY show me

0 · Reply

NasdaqPulse Apr. 24 at 1:39 PM

0 · Reply

AcceleratorModel Apr. 2 at 6:11 AM

$IQV important level here— see it if holds before earnings

0 · Reply

RunnerSignals Mar. 24 at 8:38 PM

$FIG $IQV $JEF $CHWY $AG Top stock upgrades today in the BUZZ https://stocksrunner.com/news/2026-03-24-top-stock-upgrades-today-in-the-buzz

0 · Reply

OfficialStocktwitsUser Mar. 24 at 5:38 PM

$IQV RSI: 32.99, MACD: -6.0970 Vol: 5.51, MA20: 170.24, MA50: 192.69 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

HellenJune Mar. 13 at 12:52 PM

$IQV the middleman not needed in R&D. Labourious unwanted processes that inflate the price of medicines and delay the access to the market. The parasit of the Healtchare industry. They work could be completly replaced by AI at no cost

2 · Reply

HellenJune Mar. 13 at 12:47 PM

$IQV When FDA wil update the R&D guidelines CROs will become invizible or obsolete. AI will replace their work entirely at no cost

1 · Reply

TheClockworkGroup Mar. 10 at 11:04 PM

$IQV #NYSE | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of +$1,977.56 trading #IQVIAHoldingsInc., $IQV shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader, @TradeStation & @TradingView...

0 · Reply

RunnerSignals Mar. 10 at 8:38 PM

Top stock upgrades today in the BUZZ $APLS $ASML $CAVA $IQV $PLUG steady gains post-rating changes, correlation to sector news, late buyers pushed close higher https://stocksrunner.com/news/2026-03-10-top-stock-upgrades-today-in-the-buzz

0 · Reply

IN0V8 Mar. 9 at 3:43 PM

$IQV Opportunity Barclays raises to overweight from equal-weight TD Cowen raises target price to $213 from $174 TD Cowen raises to buy from hold

0 · Reply

TheClockworkGroup Feb. 27 at 10:53 PM

$IQV #NYSE | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of +$5,422.06 trading #IQVIAHoldingsInc., $IQV shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader, @TradeStation & @TradingView...

0 · Reply

LandonCapital Feb. 25 at 5:30 PM

$IQV https://landoncapital.net/iqvia-nyse-iqv-to-acquire-drug-discovery-assets/

0 · Reply

d_risk Feb. 17 at 4:38 PM

$IQV $HLMN - Hillman Solutions Corp - 10K - Updated Risk Factors HLMN’s 2026 10-K risk revamp spotlights heavy reliance on two big-box customers post-True Value bankruptcy, deeper tariffs/China-Taiwan and international trade exposure, new ERP and cyber/IT vulnerabilities, tighter focus on inventory and working capital, more granular leverage and liquidity constraints amid volatile capital markets, and expanded IP and FX risks, while trimming M&A, legal proceedings, and seasonal/weather risk detail. #IndustrialHardware #CustomerConcentrationRisk #TradeTariffs #CybersecurityVulnerabilities #FinancialLiquidity 🟢 Added 🟠 Removed https://d-risk.ai/HLMN/10-K/2026-02-17

0 · Reply

d_risk Feb. 17 at 3:57 PM

$IQV - IQVIA Holdings Inc - 10K - Updated Risk Factors IQVIA’s 10-K risk section is now longer, more detailed, and more tech- and regulation-focused: it trims multiple execution, M&A, client concentration, tax, and capital markets risks while expanding disclosures on AI, data and third‑party dependencies, cyber/IT systems, IP protection, international operations, sustainability, restructuring, leverage covenants, and shareholder rights. #HealthcareTechnology #AIIntegration #CybersecurityRisks #RegulatoryCompliance #InternationalOperations 🟢 Added 🟠 Removed https://d-risk.ai/IQV/10-K/2026-02-17

0 · Reply

Market Cap	29.82B
Revenue (ttm)	16.31B
Net Income (ttm)	1.36B
EPS (ttm)	N/A
PE Ratio	15.84
Forward PE	15.34
Profit Margin	8.34%
Debt to Equity Ratio	2.37

Volume	1,083,000
Avg Vol	1,690,844
Day's Range	N/A - N/A
Shares Out	166.90M
Stochastic %K	86%
Beta	1.18
Analysts	Strong Sell
Price Target	$226.95